Entera Bio Ltd. (ENTX)
$3.14+0.15+5.02%Nov 6
Loading chart…
USA›Health Care›Biotechnology›Biotechnology
M.Cap$546M
Dividends—
Next report—
Forecast
Target
P/E—
P/S—
P/B1.99
5-y avg sales growth-35.1%
Debt / EBITDA0.00
ROE—
Altman Z-score5.61 (safe)
RSI59
MFI61
Price / MA50+9.2% (high) ↑
Trend pattern
Financial Statements
No data available
Team
Loading…
Leadership Changes
Sign in to view leadership changes
Sign in
No changes found
Insider Activity
Loading…
DateTypeDescription
Loading…
Earnings Transcripts
Loading…
Dividends
Loading…
Investor Presentations
Loading…
Options
Expiration from:
to:
Strike from:
to:
Loading options…
Loading bonds…
Stress Test
Loading…
About

Entera Bio is a pharmaceutical company developing large molecule drugs for unmet medical needs. EB612 and EB613 are its product candidates; EB612 is being tested for hypoparathyroidism, while EB613 has completed Phase II trials for osteoporosis and is also in Phase I trials for non-union fractures. Entera Bio has a research agreement with Amgen to develop treatments for inflammatory diseases and other serious illnesses.

https://www.enterabio.com
Beta 1.47